Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

OTC Prilosec Overdose, Interaction Concerns Discounted By P&G

This article was originally published in The Tan Sheet

Executive Summary

Andrx' suggestion that OTC Prilosec would raise the danger of overdose because the heartburn medication takes several days to work "is without basis," Procter & Gamble asserts in a recent letter to FDA

You may also be interested in...



OTC Prilosec Risk/Benefit Ratio Relative To Current OTCs Questioned By Andrx

Uncertainties about the safety and efficacy of OTC Prilosec (omeprazole 20 mg) combined with "the relative effectiveness" of currently available nonprescription acid-reducers, should cause FDA to deny Procter & Gamble/AstraZeneca's switch NDA, Andrx says in a Nov. 20 citizen petition

Prilosec 1 Labeling Could Include Brand Names Of Contraindicated Drugs

Including brand names of Rx drugs that could interact with omeprazole on Prilosec 1 labeling was advocated by members of FDA's Nonprescription and Gastrointestinal Drugs Advisory Committees

Prilosec GERD Treatment Behavior Shown In Actual Use Studies - FDA

Consumers using AstraZeneca/Procter & Gamble's Prilosec 1 (omeprazole 10 mg) to prevent heartburn are likely to take the drug for longer than the 10-day limit set in proposed OTC labeling, according to agency reviewers.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS095431

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel